The Role of Colony-Stimulating Factors and Granulocyte Transfusion in Treatment Options for Neutropenia in Children with Cancer

Pediatric Drugs

Volumn 5, Issue 10, 2003, Pages 673-684

  Liang, Der Cherng ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; DEXAMETHASONE; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANEMIA; CAPILLARY LEAK SYNDROME; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHILD; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DYSPNEA; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; FLUSHING; GRANULOCYTE PRECURSOR; GRANULOCYTE TRANSFUSION; HEADACHE; HUMAN; HYPOTENSION; INJECTION SITE; LEUKOCYTE COUNT; MALIGNANT TRANSFORMATION; MEDICAL SOCIETY; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; OXYGEN SATURATION; PNEUMONIA; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SEPSIS; SIDE EFFECT; SPLENOMEGALY; STEM CELL TRANSPLANTATION; SYSTEMIC MYCOSIS; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

ANTINEOPLASTIC AGENTS; CHILD; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; GRANULOCYTES; HUMANS; LEUKOCYTE TRANSFUSION; NEOPLASMS; NEUTROPENIA; PRACTICE GUIDELINES;

EID: 0242383539     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200305100-00003     Document Type: Review

References (114)

1. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323-32
2. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966: 64: 32-40
3. Wingard JR, Santos GW, Saral R. Differences between first and subsequent fevers during prolonged neutropenia. Cancer 1987; 59: 844-9
4. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551-73
5. Rubin M, Hathorn JW, Pizzo PA. Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 1988; 6: 167-84
6. Marsh JC, Boggs DR, Cartwright GE, et al. Neutrophil kinetics in acute infection. J Clin Invest 1967; 46: 1943-53
7. Shivdasani RA, Orkin SH. The transcriptional control of hematopoiesis. Blood 1996; 87; 4025-39
8. Metcalf D. Clonal culture of hemopoietic cells. Amsterdam: Elsevier/ North American Biomedical Press, 1984
9. Finiewicz KJ, Wingard JR. Cytokines and WBC transfusions. In: Rolston KVI, Rubenstein EB, editors. Textbook of febrile neutropenia. London: Martin Dunitz, 2001: 245-81
10. Abegg AL, Vickery LE, Bremer ME, et al. The enhanced in vitro hematopoietic activity of leridistim, a chimeric dual G-CSF and IL-3 receptor agonist. Leukemia 2002; 16: 316-26
11. Dale DC, Liles WC, Summer WR, et al. Review: granulocyte colony-stimulating factor: role and relationships in infectious diseases. J Infect Dis 1995; 172: 1061-75
12. Hammond WP, Csiba E, Canin A, et al. Chronic neutropenia: a new canine model induced by human granulocyte colony-stimulating factor. J Clin Invest 1991; 87: 704-10
13. Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84: 1737-46
14. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791-808
15. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992; 327 (2 Pt 1): 28-35
16. Bonig H, Silbermann S, Weller S, et al. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF): results of a prospective randomised monocentre study. Bone Marrow Transplant 2001; 28: 259-64
17. D'Andrea AD. Cytokine receptors in congenital hematopoietic disease. N Engl J Med 1994; 330: 839-46
18. Avalos BR. Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 1996; 88: 761-77
19. Chatta GS, Price TH, Allen RC, et al. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84: 2923-9
20. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996; 88: 335-40
21. Tanaka H, Satake-Ishikawa R, Ishikawa M, et al. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. Cancer Res 1991; 51: 3710-4
22. van der Auwera P, Platzer E, Xu ZX, et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (RO 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol 2001; 66: 245-51
23. Takeshita A, Saito H, Toyama K, et al. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia. Int J Hematol 2000; 71: 136-43
24. Liles WC, Huang JE, van Burik JH, et al. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens. J Infect Dis 1997; 175: 1012-5
25. Gaviria JM, van Burik JA, Dale DC, et al. Comparison of interferon-gamma, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor for priming leukocyte-mediated hyphal damage of opportunistic fungal pathogens. J Infect Dis 1999; 179: 1038-41
26. Liles WC, Rodger ER, Dale DC. Differential regulation of human neutrophil surface expression of CD14, CD11b, CD18, and L-selection following the administration of G-CSF in vivo and in vitro [abstract]. Clin Res 1994; 42: 304A
27. Stroncek DF, Jaszcz W, Herr GP, et al. Expression of neutrophil antigens after 10 days of granulocyte-colony-stimulating factor. Transfusion 1998; 38: 663-8
28. Liles WC, Klebanoff SJ. Regulation of apoptosis in neutrophils: fas track to death? J Immunol 1995; 155: 3289-91
29. Aglietta M, Piacibello W, Sanavio F, et al. Kinetics of human hematopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. J Clin Invest 1989; 83: 551-7
30. Carr PD, Gustin SE, Church AP, et al. Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell 2001; 104: 291-300
31. Foulke RS, Marshall MH, Trotta PP, et al. In vitro assessment of the effects of granulocyte-macrophage colony-stimulating factor on primary human tumors and derived lines. Cancer Res 1990; 50: 6264-7
32. Gasson JC. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 1131-45
33. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998; 92: 4491-508
34. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-508
35. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1996; 14: 1957-60
36. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558-85
37. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992; 327 (2 Pt 2): 99-106
38. Lifton R, Bennett JM. Clinical use of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in neutropenia associated with malignancy. Hematol Oncol Clin North Am 1996; 10: 825-39
39. Welte K, Reiter A, Mempel K, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood 1996; 87: 3143-50
40. Riikonen P, Rahiala J, Salonavaara M, et al. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Stem Cells 1995; 13: 289-94
41. Pui C-H, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphocytic leukemia. N Engl J Med 1997; 336: 1781-7
42. Laver J, Amylon M, Desai S, et al. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. J Clin Oncol 1998; 16: 522-6
43. Rubino C, Laplanche A, Patte C, et al. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma. J Natl Cancer Inst 1998; 90: 750-5
44. Little MA, Morland B, Chisholm J, et al. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol 2002; 38: 98-103
45. Heath JA, Steinherz PG, Altman A, et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group study. J Clin Oncol 2003; 21: 1612-7
46. Schaison G, Eden OB, Henze G, et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr 1998; 157: 955-66
47. Crawford J, Glaspy J, Vincent M, et al. Effect of filgrastim (R-METHUG-CSF) on oral mucositis in patients with small cell lung cancer (SCLC) receiving chemotherapy (cyclophosphamide, doxorubicin, and etoposide, CAE) [abstract]. Proc Am Soc Clin Oncol 1994; 13: 442
48. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991; 325: 164-70
49. Wexler LH, Weaver-McClure L, Stenberg SM, et al. Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol 1996; 14: 901-10
50. Burdach SE, Muschenich M, Joseph W, et al. Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors: results of a prospective randomized study. Cancer 1995; 76: 510-6
51. Soda H, Oka M, Fukuda M, et al. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. Cancer Chemother Pharmacol 1996; 38: 9-12
52. Hartman LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997; 336: 1776-80
53. Gerhartz HH, Engelhard M, Meusers P, et al. Randomized, double-blind placebo-controlled, phase II study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-risk malignant non-Hodgkin's lymphoma. Blood 1993; 82: 2329-39
54. Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 492-501
55. Garcia-Carbonero R, Mayordomo JI, Tomamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001; 93: 31-8
56. Mayordomo JI, Rivera F, Diaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995; 87: 803-8
57. Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients: a systemic review of the literature with meta-analysis. Support Care Cancer 2002; 10: 181-8
58. Mitchell PL, Morland B, Stevens MC, et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol 1997; 15: 1163-70
59. Riikonen P, Saarinen UM, Makipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J 1994; 13: 197-202
60. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1997; 90: 2952-61
61. Witz F, Sadoun A, Perrin M-C, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998; 91: 2722-30
62. Nademanee A, Sniecinski I, Schmidt GM, et al. High-dose chemotherapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor mobilized peripheral blood stem cells. J Clin Oncol 1994; 12: 2176-86
63. Snowden JA, Biggs JC, Milliken ST, et al. A randomized blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for hematopoietic stem cell mobilization in patients with severe rheumatoid arthritis. Bone Marrow Transplant 1998; 22: 1035-41
64. Schmitz N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-7
65. Ho AD, Young D, Maruyama M, et al. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs a combination of both. Exp Hematol 1996; 24: 1460-8
66. Winter JN, Lazarus HM, Rademaker A, et al. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 1996; 14: 277-86
67. Meisenberg B, Brehm T, Schmeckel A, et al. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than glanulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells. Transfusion 1998; 38: 209-15
68. Cesana C, Carlo-Stella C, Regazzi E, et al. CD34+ cells mobilized by cyclophosphamide and granulocyte colony stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Bone Marrow Transplant 1998; 21: 561-8
69. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95: 1588-93
70. Weisdorf D, Miller J, Verfaillie C, et al. Cytokine-primed bone marrow stem cells vs peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs G-CSF. Biol Blood Marrow Transplant 1997; 3: 217-23
71. Becker PS, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3: 45-9
72. Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilization in a healthy donor [letter]. Lancet 1999; 353: 555
73. Anderlini P, Korbling M, Dale D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903-8
74. Cleaver S, Goldman J. Use of G-CSF to mobilise PBSC in normal healthy donors: an international survey. Bone Marrow Transplant 1998: 21 Suppl. 3: S29-31
75. Anderlini P, Pzrepiorka D, Korbling M, et al. Blood stem cell procurement: donor safety issues. Bone Marrow Transplant 1998; 21 Suppl. 3: S35-9
76. Faucher C, Le Corroller AG, Chabannon C, et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996; 17: 533-6
77. Bence-Bruckler I, Bredeson C, Atkins H, et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 postautologous stem cell transplantation. Bone Marrow Transplant 1998; 22: 965-9
78. Ciernik IF, Schanz U, Gmur J. Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant 1999: 24: 147-51
79. Hagglud H, Ringden O, Oman S, et al. A prospective randomized trial of filgrastim (γ-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1999: 24: 831-6
80. Torres Gomez A, Jimenez MA, Alvarez MA, et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation: a prospective randomized study. Ann Hematol 1995; 71: 65-70
81. Stahel RA, Jost LM, Honegger H, et al. Randomized trial showing efficacy of filgrastim 5 μg/kg/day and 10 μg/kg/day following high dose chemotherapy and autologous bone marrow transplantation in high risk lymphomas. J Clin Oncol 1997; 15: 1730-5
82. Parsons SK, Mayer DK, Alexander SW, et al. Growth factor practice patterns among pediatric oncologists: results of a 1998 Pediatric Oncology Group survey. J Pediatr Hematol Oncol 2000; 22: 227-41
83. Stute N, Furman WL, Schell M, et al. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. J Pharm Sci 1995; 84: 824-8
84. Honkoop AH, Hoekman K, Wagstaff J, et al. Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously. Br J Cancer 1996; 74: 1132-6
85. Eguchi K, Sasaki S, Kunitou H, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients with lung cancer [abstract]. Proc Am Soc Clin Oncol 1989; 8: 239
86. Crawford J, Kreisman H, Garewal H, et al. The impact of filgrastim schedule variation on hematopoietic recovery postchemotherapy. Ann Oncol 1997; 8: 1117-24
87. Broxmeyer HE, Benninger L, Patel S, et al. Kinetic response of human marrow progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response with granulocyte-macrophage colony-stimulating factor. Exp Hematol 1994; 22: 100-2
88. Beveridge RA, Miller JA, Kales AN, et al. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 1998; 16: 366-73
89. Root RK, Dale DC. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in non-neutropenic patients. J Infect Dis 1999; 179 Suppl. 2: S342-52
90. Peters WP, Shogan J, Shpall EJ, et al. Recombinant human granulocyte-macrophage colony-stimulating factor produces fever [letter]. Lancet 1988; I: 950
91. Hubel K, Dale DC, Liles C. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stuimulating factor, macrophage colony-stimulating factor, and interferon-γ. J Infect Dis 2002; 185: 1490-501
92. Spitzer G, Adkins D, Mathews M, et al. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant 1997; 20: 921-30
93. Itoh Y, Kuratsuji T, Tsunawaki S, et al. In vivo effects of recombinant human granulocyte colony-stimulating factor on normal neutrophil function and membrane effector molecule expression. Int J Hematol 1991; 54: 463-9
94. Freedman M. Safety and long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia. Curr Opin Hematol 1997; 4: 217-24
95. Lieschke GJ, Cebon J, Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 2634-43
96. Arnig M, Kliche KO, Schneider W. GM-CSF therapy and capillary-leak syndrome [letter]. Ann Hematol 1991; 62: 83
97. Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996; 14: 1371-82
98. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996; 14: 2150-9
99. Brodsky RA, Bedi A, Jones RJ. Are growth factors leukemogenic? Leukemia 1996; 10: 175-7
100. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999; 17: 3374-88
101. Kushner BH, Heller G, Cheung N-K, et al. High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J Clin Oncol 1998; 16: 3016-20
102. Micallef IN, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 974-55
103. Rodriquez-Galindo C, Poquette CA, Marina NM, et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol 2000; 22: 321-9
104. Dutcher JP. Granulocyte transfusion therapy in patients with malignancy. In: Dutcher JP, editor. Modern transfusion therapy. Boca Raton (FL): CRC Press, 1990: 135-56
105. Relling MV, Boyett JM, Blanco JG, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101: 3862-7
106. Vamvakas EC, Pineda AA. Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis. J Clin Apheresis 1997; 12: 74-81
107. Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietics stem cell transplantation. Blood 2000; 95: 3302-9
108. Price TH. The current prospects for neutrophil transfusions for the treatment of granulocytopenic infected patients. Transfus Med Rev 2000; 14: 2-11
109. Leavey PJ, Thurman G, Ambruso DR. Functional characteristics of neutrophils collected and stored after administration of G-CSF. Transfusion 2000; 40: 414-9
110. Maakestad K, Mazanet R, Liles WC, et al. Neutrophil transfusion for treatment of infections. In: Morstyn G, Sheridan W, editors. Cell therapy. Cambridge: Cambridge University Press, 1996: 510-26
111. Menitove JE, Abrams RA. Granulocyte transfusion in neutropenic patients. Crit Rev Oncol Hematol 1987; 7: 89-113
112. Klein HG, Strauss RG, Schiffer CA. Granulocyte transfusion therapy. Semin Hematol 1996; 33: 359-68
113. Dry SM, Bechard KM, Milford EL, et al. The pathology of transfusion-related acute lung injury. Am J Clin Pathol 1999; 112: 216-21
114. Lee JJ, Chung IJ, Ahn YK, et al. Life-threatening paroxysmal supraventricular tachycardia developed during granulocyte transfusion therapy for neutropenia-related infection. Leukemia 2000; 14: 1324-5